Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03875131 · ClinicalTrials.gov registry record
Definition, Quantification, and Utility of Biomarkers of Repetitive Brain Injury in Predicting Concussion and Other Long-Term Injury Risks in Patients With Atrial Fibrillation (Concussion AF)
A clinical trial, sponsored by Intermountain Health Care.
- Completed
- Registry status
- 120
- Enrollment target
NCT03875131 is a clinical trial that has completed, run by Intermountain Health Care. The registered enrollment target is 120 participants.
The verdict
NCT03875131 has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
This is a prospective clinical study designed to evaluate biomarkers of brain injury and dementia incidence and moderate cognitive decline rates in moderate- to high-risk atrial fibrillation patients that undergo standard of care atrial fibrillation management.
Interventions
- OTHER Biomarkers of Dementia and Cognitive Decline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-07-15 |
| Est. Completion | 2022-10-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03875131
The ClinicalTrials.gov registry entry for NCT03875131 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biomarkers of Dementia and Cognitive Decline is the first listed.
NCT03875131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03875131 about?
NCT03875131 is a clinical study titled "Definition, Quantification, and Utility of Biomarkers of Repetitive Brain Injury in Predicting Concussion and Other Long-Term Injury Risks in Patients With Atrial Fibrillation (Concussion AF)". This is a prospective clinical study designed to evaluate biomarkers of brain injury and dementia incidence and moderate cognitive decline rates in moderate- to high-risk atrial fibrillation patients that undergo standard of care atrial fibrillation management.
What is the current status of trial NCT03875131?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2017-07-15. Estimated completion is 2022-10-24.
What interventions are being tested in trial NCT03875131?
The interventions under investigation include: Biomarkers of Dementia and Cognitive Decline (OTHER).
Who is sponsoring clinical trial NCT03875131?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.